World Molecular Diagnostics Market Opportunities in 90 Countries-2021-2025 Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests-Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
This new 90-country survey from LeadingMarketResearch.com provides granular data and analysis not available from any other source.
The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget.
Highlights
The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.
In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.
Geographic Regions and Countries
Asia-Pacific
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Europe
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
North America
Canada, Mexico, USA
Market Segmentation Analysis
The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget.
Highlights
- Supplier sales and market shares in major countries
- Five-year test volume and sales forecasts
- Strategic profiles of market players and start-up firms developing innovative technologies and products
- Emerging technologies
- Review of molecular diagnostic analyzers
- Specific product and business opportunities for instrument and consumable suppliers
The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.
In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.
Geographic Regions and Countries
Asia-Pacific
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Europe
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
North America
Canada, Mexico, USA
Market Segmentation Analysis
- Sales and market shares of key suppliers of molecular diagnostic reagent kits and components in major markets.
- Five-year test volume and sales forecasts for major applications, including:
- Infectious Diseases
- Forensic Testing
- Cancer
- Paternity Testing/HLA Typing
- Genetic Diseases
- Others
- Five-year test volume and sales projections for over 30 NAT assays.
- A comprehensive analysis of the sequencing market, by country and laboratory segment, including:
- Industrial
- Academic
- Government
- Commercial
- Market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and suppliers in major countries.
- Comparison of leading molecular diagnostic analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.
- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods.
- Universities and research centers developing new molecular diagnostic technologies and products.
- Universities and research centers developing new molecular diagnostic technologies and products.
- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.
- Companies developing and marketing molecular diagnostics products, by test and application.
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Business planning issues and concerns.
I. INTRODUCTION
II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
IV. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. WORLDWIDE MARKET AND TECHNOLOGY REVIEW
A. DNA Sequencing
B. DNA and RNA Probe Technologies
C. Detection Technologies
D. Instrumentation
Review of latest analyzers from Abbott, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic, Qiagen, Roche, Siemens Healthineers, and other suppliers.
E. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
Liquid Transportation and Mixing
Separation
Reaction
Detection
F. Pharmacogenomics
G. Major Applications
1. Microbiology/Infectious Diseases
a. Overview
b. Major Infectious Diseases
AIDS/HIV
Adenovirus
Aeromonads
Anthrax/Bacillus Anthracis
Arboviruses
Babesiosis
Bacillary Epithelioid Angiomatosis (BEA), other Bartonella (Rochalimaea)
Blastocystis Hominis
Brucella
Campylobacter
Candida
Chagas Disease
Chancroid
Chlamydia
Clostridium Difficile
Coronaviruses
Coxsackieviruses
Creutzfeldt-Jakob’s Disease
Cryptosporidium Parvum
Cyclospora Cayetanensis
Cytomegalovirus
Ebola Virus
E. Coli
EchoVirus
Encephalitis
Enteroviruses
Epstein-Barr Virus
Giardia Lamblia
Gonorrhea
Granuloma Inguinale
Hantavirus
Helicobacter Pylori
Hepatitis
Herpes Simplex Virus
Human Herpes Virus-6 (HHV-6)
Influenza Viruses
Legionella
Lyme Disease
Lymphogranuloma Venereum (LGV)
Malaria
Measles (Rubeo la)
Meningitis
Microsporidium
Mononucleosis
Mumps
Mycoplasma
Papillomaviruses
Parvovirus B19
Pneumonia
Polyomaviruses
Pseudomonas Aeruginosa
Rabies
Respiratory Syncytial Virus (RSV)
Rhinoviruses
Rotavirus
Rubella
Salmonellosis
Septicemia
Shigellosis
Staphylococcus Aureus
Streptococci
Syphilis
Toxoplasmosis
Trichomonas Vaginalis
Tuberculosis
Vibrio
West Nile Virus
Yersina
2. Cancer Testing
a. Overview
b. Major Cancer Types
Prostate
Lung
Colon and Rectum
Breast
Skin
Uterine
Leukemia
Oral
c. Oncogenes
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
3. Genetic Diseases
a. Overview
b. Nucleic Acid Amplification
c. Chromosome Imaging
d. Genomics Technologies
e. Proteomics Technologies
f. Current Pharmacogenomic Tests
g. Future Pharmacogenomic Testing
h. Major Diseases
Achondroplasia
Autosomal Dominant Polycystic Kidney Disease
Cancer
Cosmetogenomics
Cystic Fibrosis
Down's Syndrome
Duchenne and Becker Muscular Dystrophy
Factor V (Leiden)
Factor IX Deficiency
Fragile X Syndrome
Heart Disease
Hemochomatosis
Hemophilia
Huntington's Disease
Maternal-Fetal Incompatibility
Multiple Endocrine Neoplasia
Phenylketonuria (PKU)
Polycystic Kidney Disease (PKD)
Prenatal Screening
Retinitis Pigmentosa
Retinoblastoma
Sickle Cell Anemia
Spinal Muscular Atrophy
Vitamin B12 Metabolism
i. Social Issues and Concerns
4. Forensic Testing
a. Overview
b. Multilocus and Single Locus Probes
c. DNA Profile Data Banks
d. Judicial Implementation
e. Major Crime Categories
f. Factors Contributing to the DNA Probe Market Expansion
Technology Availability
Use of Hair as Evidence
g. Wildlife Forensics
5. Paternity Testing/HLA Typing
6. Other Applications
a. Disease Susceptibility Testing
b. Cardiovascular Diseases
c. Diabetes
d. Alzheimer's Disease
e. Periodontal Disease
f. Plasma Purification
g. Organ Transplantation
h. Water Contamination
i. Other
H. Competing/complementing
1. Monoclonal Antibodies/Immunoassays
2. RNA Probes
3. Two-Dimensional Electrophoresis
4. Flow Cytometry
VII. COUNTRY MARKET ANALYSES: MOLECULAR DIAGNOSTIC ANALYZERS AND REAGENT MARKET SHARES AND FORECASTS FOR 100 TESTS--VOLUME AND SALES FORECASTS FOR 90 COUNTRIES
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
VIII. COMPETITIVE ASSESSMENTS
The report provides strategic assessments of over 40 leading molecular diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott, Agilent Technologies, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Enzo, Fujirebio, Grifols, Hologic, Illumina, LabCorp/Sequenom, Leica Biosystems, Myriad Genetics, Ortho-Clinical Diagnostics, Qiagen, Quest Diagnostics, Quidel, Roche, Shimadzu, Siemens Healthineers, Sierra Molecular, Takara Bio, Tecan Group, Thermo Fisher, and others.
IX. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING INNOVATIVE MOLECULAR DIAGNOSTIC TECHNOLOGIES AND PRODUCTS
II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
IV. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. WORLDWIDE MARKET AND TECHNOLOGY REVIEW
A. DNA Sequencing
B. DNA and RNA Probe Technologies
C. Detection Technologies
D. Instrumentation
Review of latest analyzers from Abbott, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic, Qiagen, Roche, Siemens Healthineers, and other suppliers.
E. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
Liquid Transportation and Mixing
Separation
Reaction
Detection
F. Pharmacogenomics
G. Major Applications
1. Microbiology/Infectious Diseases
a. Overview
b. Major Infectious Diseases
AIDS/HIV
Adenovirus
Aeromonads
Anthrax/Bacillus Anthracis
Arboviruses
Babesiosis
Bacillary Epithelioid Angiomatosis (BEA), other Bartonella (Rochalimaea)
Blastocystis Hominis
Brucella
Campylobacter
Candida
Chagas Disease
Chancroid
Chlamydia
Clostridium Difficile
Coronaviruses
Coxsackieviruses
Creutzfeldt-Jakob’s Disease
Cryptosporidium Parvum
Cyclospora Cayetanensis
Cytomegalovirus
Ebola Virus
E. Coli
EchoVirus
Encephalitis
Enteroviruses
Epstein-Barr Virus
Giardia Lamblia
Gonorrhea
Granuloma Inguinale
Hantavirus
Helicobacter Pylori
Hepatitis
Herpes Simplex Virus
Human Herpes Virus-6 (HHV-6)
Influenza Viruses
Legionella
Lyme Disease
Lymphogranuloma Venereum (LGV)
Malaria
Measles (Rubeo la)
Meningitis
Microsporidium
Mononucleosis
Mumps
Mycoplasma
Papillomaviruses
Parvovirus B19
Pneumonia
Polyomaviruses
Pseudomonas Aeruginosa
Rabies
Respiratory Syncytial Virus (RSV)
Rhinoviruses
Rotavirus
Rubella
Salmonellosis
Septicemia
Shigellosis
Staphylococcus Aureus
Streptococci
Syphilis
Toxoplasmosis
Trichomonas Vaginalis
Tuberculosis
Vibrio
West Nile Virus
Yersina
2. Cancer Testing
a. Overview
b. Major Cancer Types
Prostate
Lung
Colon and Rectum
Breast
Skin
Uterine
Leukemia
Oral
c. Oncogenes
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
3. Genetic Diseases
a. Overview
b. Nucleic Acid Amplification
c. Chromosome Imaging
d. Genomics Technologies
e. Proteomics Technologies
f. Current Pharmacogenomic Tests
g. Future Pharmacogenomic Testing
h. Major Diseases
Achondroplasia
Autosomal Dominant Polycystic Kidney Disease
Cancer
Cosmetogenomics
Cystic Fibrosis
Down's Syndrome
Duchenne and Becker Muscular Dystrophy
Factor V (Leiden)
Factor IX Deficiency
Fragile X Syndrome
Heart Disease
Hemochomatosis
Hemophilia
Huntington's Disease
Maternal-Fetal Incompatibility
Multiple Endocrine Neoplasia
Phenylketonuria (PKU)
Polycystic Kidney Disease (PKD)
Prenatal Screening
Retinitis Pigmentosa
Retinoblastoma
Sickle Cell Anemia
Spinal Muscular Atrophy
Vitamin B12 Metabolism
i. Social Issues and Concerns
4. Forensic Testing
a. Overview
b. Multilocus and Single Locus Probes
c. DNA Profile Data Banks
d. Judicial Implementation
e. Major Crime Categories
f. Factors Contributing to the DNA Probe Market Expansion
Technology Availability
Use of Hair as Evidence
g. Wildlife Forensics
5. Paternity Testing/HLA Typing
6. Other Applications
a. Disease Susceptibility Testing
b. Cardiovascular Diseases
c. Diabetes
d. Alzheimer's Disease
e. Periodontal Disease
f. Plasma Purification
g. Organ Transplantation
h. Water Contamination
i. Other
H. Competing/complementing
1. Monoclonal Antibodies/Immunoassays
2. RNA Probes
3. Two-Dimensional Electrophoresis
4. Flow Cytometry
VII. COUNTRY MARKET ANALYSES: MOLECULAR DIAGNOSTIC ANALYZERS AND REAGENT MARKET SHARES AND FORECASTS FOR 100 TESTS--VOLUME AND SALES FORECASTS FOR 90 COUNTRIES
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
VIII. COMPETITIVE ASSESSMENTS
The report provides strategic assessments of over 40 leading molecular diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott, Agilent Technologies, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Enzo, Fujirebio, Grifols, Hologic, Illumina, LabCorp/Sequenom, Leica Biosystems, Myriad Genetics, Ortho-Clinical Diagnostics, Qiagen, Quest Diagnostics, Quidel, Roche, Shimadzu, Siemens Healthineers, Sierra Molecular, Takara Bio, Tecan Group, Thermo Fisher, and others.
IX. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING INNOVATIVE MOLECULAR DIAGNOSTIC TECHNOLOGIES AND PRODUCTS
